Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Leukemia, Myeloid, Acute 16Myelodysplastic Syndromes 9Lung Neoplasms 5Myeloproliferative Disorders 4Leukemia, Myelomonocytic, Chronic 4Sarcoma 3Prostatic Neoplasms 3Ovarian Neoplasms 3Head and Neck Neoplasms 3Breast Neoplasms 3Stomatitis 2Primary Myelofibrosis 2Neoplasm Metastasis 2Multiple Myeloma 2Mucositis 2Melanoma 2Lymphoma, Non-Hodgkin 2Leukemia, Monocytic, Acute 2Leukemia, Lymphocytic, Chronic, B-Cell 2Leukemia, Biphenotypic, Acute 2Disease 2Carcinoma, Non-Small-Cell Lung 2Uveal Melanoma 1Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Thrombocythemia, Essential 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma, Synovial 1Prostate Cancer Metastatic 1Polycythemia Vera 1

Interventions

Gemcitabine 57Paclitaxel 50Cyclophosphamide 45pembrolizumab 44Carboplatin 41Bevacizumab 38Cisplatin 33Docetaxel 31Fluorouracil 30Nivolumab 29Capecitabine 29Pemetrexed 24Irinotecan 24Oxaliplatin 23Dexamethasone 23Ipilimumab 22Leucovorin 21Radiotherapy 20Sorafenib 19Doxorubicin 19Everolimus 18Cetuximab 18fludarabine 17Albumin-Bound Paclitaxel 17trametinib 15Sunitinib 15Rituximab 15Erlotinib Hydrochloride 15130-nm albumin-bound paclitaxel 15Prednisone 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Neoplasms × Injections × Clear all
NCT02751528 2025-01-13

QUILT-3.013: Study of Ad5 [E1-, E2b-]-HER2/Neu Vaccine (ETBX-021) in Subjects With Unresectable Locally Advanced or Metastatic HER2-Expressing Breast Cancer

NantBioScience, Inc.

Phase 1 Terminated
3 enrolled 10 charts
Breast

Breast Neoplasms, Neoplasm Metastasis, Neoplasms, Breast Neoplasms, Male

Data powered by HemOnc (CC BY 4.0) Colophon âš¡